Navigation Links
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Date:1/7/2008

lowering agent for high risk patients for whom conventional therapies are not sufficient. This potential blockbuster is a very Genzyme-like product. It provides significant benefit over the standard of care, targets a well-defined and severely ill patient population, and offers meaningful revenue and earnings potential."

"We feel that Genzyme is the perfect partner for Isis and for mipomersen," said Stanley Crooke, chairman, president and chief executive officer of Isis. "We have been very pleased with the quality and depth of interest in this flagship drug in our cardiovascular pipeline, and as we evaluated the licensing terms from various parties, we felt that Genzyme would value mipomersen appropriately as a pipeline-transforming product. This commitment to mipomersen, along with Genzyme's strength in drug development and marketing, made this relationship strategically compelling."

Mipomersen License

Mipomersen, formerly ISIS 301012, is a lipid-lowering drug targeting apolipoprotein B-100. Currently in phase 3 development, mipomersen has been shown in phase 2 trials to reduce cholesterol and other atherogenic lipids more than 40 percent beyond reductions achieved with current standard lipid-lowering drugs, enabling more patients to achieve lipid targets. These trials have shown that the treatment is well-tolerated, has a strong safety profile, and works equally well in the presence and absence of other lipid-lowering therapies including statins. A weekly injectable therapeutic, mipomersen is being developed primarily for patients at significant cardiovascular risk who are unable to achieve target cholesterol levels with statins alone or who are intolerant of statins. The drug has strong, broad patent protection.

Mipomersen's initial indication will be for patients with familial hypercholesterolemia (FH), with an anticipated filing in 2009. There are approximately 1.5 million people in the United States and Europe with FH, an inherited
'/>"/>

SOURCE Genzyme Corp.; Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
2. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
3. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
4. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
5. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
6. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
7. Genzyme Launches Cholestagel(R) in Europe
8. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
9. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
10. Genzyme Recognized by Scientists as a Top Employer
11. Genzyme Receives Approval to Market Elaprase(R) in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... CA (PRWEB) May 05, 2015 ... Life Science Animal Health, Jeffrey Schaffer, DVM, as ... “With over 15 years of experience in the ... a great addition to our veterinarian lead organization”. ... Officer, explains. “Dr. Schaffer will be responsible for ...
(Date:5/5/2015)... IN (PRWEB) May 05, 2015 The ... the state of Indiana, led by Indiana Gov. Mike ... Day. The AMA Foundation will host a Family Fest ... celebration. All proceeds will benefit the Wounded Warrior Project. ... the Academy of Model Aeronautics—the country’s foremost organization for ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 A comment ... a wide range of key photonics technologies – regulations ... competitiveness of U.S. industry. To help the community understand ... 12 May on the proposed changes to U.S. ... covered by International Traffic in Arms Regulations (ITAR). , ...
(Date:5/5/2015)... 5, 2015  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... 2015 on Friday, May 8 before the market opens. ... and conference call at 8:30 a.m. Eastern Time (5:30 ... be accessed by phone by calling (800) 708-4540 (domestic) ... can be accessed live on the Investors section of ...
Breaking Biology Technology:Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2State of Indiana proclaims August 15 as Model Aviation Day 2Comments needed now from photonics industry on revisions of U.S. export rules 2Comments needed now from photonics industry on revisions of U.S. export rules 3Comments needed now from photonics industry on revisions of U.S. export rules 4
... Sciences, LLC (IDS),with its strategic science partner the Idaho ... Award for AbP ID(TM), a new groundbreaking,forensic human identification ... labs in late 2009 or early 2010, will be ... accurate, reliable results in as,little as two hours., ...
... Orexigen(R) Therapeutics,Inc. (Nasdaq: OREX ), a biopharmaceutical ... nervous system-related disorders, today,announced that Dr. Dennis Kim has ... Obesity and Metabolic Disorders. Dr. Kim will be,leading the ... am thrilled to be joining the team at Orexigen ...
... 3 Data Offers Additional,Information on Bazedoxifene Alone, ... retrospective analysis of,Phase 3 two-year data presented ... American,Menopause Society (NAMS) suggest that postmenopausal women ... of,breast tenderness and abnormal mammograms no greater ...
Cached Biology Technology:New, Fast Forensic Technology Wins R&D 100 Award 2Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders 2Retrospective Analysis of Phase 3 Data Suggest Wyeth's Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms 2Retrospective Analysis of Phase 3 Data Suggest Wyeth's Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms 3Retrospective Analysis of Phase 3 Data Suggest Wyeth's Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms 4
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... 2, 2015 At its 2015 ACMG Annual ... , the American College of Medical Genetics and ... to its Board.  Members of the ACMG Board of ... forming and advancing its policies and programs. ACMG is ... "It,s an eventful time in medical genetics and ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... ORLANDO, Nov. 6 Downing an energy drink may ... in a small study presented at the American Heart ... Wayne State University researchers, blood pressure and heart rate ... a day of a popular energy drink., While the ...
... has published a new analysis showing that as plant species ... and contain fewer total plants a situation that could ... The article is to appear in the online ... the week of Nov. 5. The process by which ...
... today its involvement in an expanded access program ... for phenylketonuria (PKU), a rare genetic metabolic disorder ... can result in severe mental retardation. Currently, there ... program at Nationwide Childrens. Under an expanded ...
Cached Biology News:Energy drinks may pose risks for people with high blood pressure, heart disease 2Energy drinks may pose risks for people with high blood pressure, heart disease 3Scientists warn that species extinction could reduce productivity of plants on Earth by half 2Nationwide Children's Hospital involved in expanded access program for treatment of PKU 2
... liquid handling system from Molecular Devices provides ... one instrument. The system handles a variety ... washing96-, 384- and 1536-welland is the first ... has been optimized to dispense from four ...
... Plate consists of an anodized aluminum body ... Fluorescent Compounds embedded in polymerized matrix. It ... FLx800 and Synergy Multi-Detection Readers. This multi-functional ... while reducing the need for tedious wet ...
... the SMZ line is a Greenough stereomicroscope designed ... It is available with a choice of a ... compact base (N2GG). This microscope can be easily ... all at the same time giving you ultimate ...
... for siRNA applications, contains magnetic nanoparticles (MagTag) ... acid of interest. Exploiting magnetic force the ... drawn towards and delivered into the target ... can be used for adherent cells; for ...
Biology Products: